A phase 3 bardoxolone methyl evaluation in patients with chronic kidney disease and T2DM (BEACON) trial (NCT01611569) in 2185 patients with T2DM and stage 4 chronic kidney disease showed that BAR transiently increased eGFR and reduced urine albumin-to-creatinine ratio. Here, ALB is linked to chronic kidney disease.